Because anti‐PD‐1 antibody19, 20, 21, 22 and anti‐CTLA4 antibody23 that suppress suppressor T cells can be formulated and effectively used in human cancers and might markedly activate carrier cell‐induced CTLs, we expect that the antitumor effect of carrier cell therapy could be further increased by combination with these preparations. The gene discussed is CTLA4; the disease is cancer.